Abstract: The invention relates to a plasma derived immunoglobulin G concentrate and to the process for producing said concentrate. The process comprises a series of chromatographic separations but no ethanol precipitation. The process also includes a viral inactivation treatment. The invention relates to the immunoglobulin G concentrate obtained by said process which is of therapeutic quality suitable for any use especially for intraveinous injection.

Abstract: The invention relates to a process for preparing a concentrate of Factor VIII-von Willebrand factor complex having high specific activity from total (non-cryoprecipitated) plasma.The process comprises pre-purifying by means of a double treatment with barium chloride and with aluminium hydroxide.The process then comprises purification by chromatography on an anion exchange resin, of the DEAE-Fractogel type.The process includes a step of viral inactivation by means of a treatment with solvent-detergent.The process also makes it possible to recover fibrinogen, albumin, immunoglobulins, antithrombin III, fibronectin and prothrombin complex, from the same plasma.The different concentrates obtained using the process according to the invention are intended, in particular, for therapeutic use.

Abstract: The invention relates to a process for purifying human von Willebrand factor from a cryoprecipitated plasma fraction, which comprises a combination of three chromatographic separation steps. The first chromatographic separation step comprises contacting a cryoprecipitated fraction with a large-pore vinyl polymer resin having DEAE group. The effluent from this separation step is again contacted with a large pore vinyl polymer resin having DEAE groups in the second chromatographic step. In the third chromatographic separation step, the effluent from the second step is subjected to affinity chromatography by contacting with gelatin-Sepharose. The concentrate obtained has very high specific activity and a high percentage of high molecular weight multimers. The concentrate is intended, in particular, for therapeutic use.

Abstract: The invention provides a thrombin coagulable protein concentrate,, the preparation thereof and the therapeutic use thereof. This concentrate has a fibrinogen content greater than 70% and a sufficient amount of endogenous Factor XIII. It may be solubilized at ambient temperature. Its preparation comprises at least one cold precipitation step with dilute ethanol and uses total plasma as a starting product. The concentrate of the invention makes it possible more particularly to obtain an injectable fibrinogen and a biological glue of high quality.

Abstract: The invention relates to a human Factor XI concentrate having high specific activity prepared using a process comprising a filtration-adsorption step and a single step of chromatography on cation exchange resin.The concentrate obtained is perfectly suitable for therapeutic use in replacement therapy in cases of Factor XI deficiency.

Abstract: The invention relates to a process for separating proteins from a fraction of human or animal plasma.According to this process, a solubilized fraction of cryoprecipitated plasma is subjected to a single stage of chromatography on a moderately ionic anion exchange resin permitting hydrophobic interactions to take place, which does not adsorb certain proteins and fixes others, which are then eluted by increasing the ionic strength of the buffer by the addition of NaCl.The process according to the invention makes it possible, in particular, to obtain a Factor VIII concentrate of high purity that can be used for the treatment of haemophilia A. The process also makes it possible to obtain concentrates of fibrinogen, Von Willebrand's factor and fibronectin.